These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 11437188)

  • 1. Rasburicase.
    Easton J; Noble S; Jarvis B
    Paediatr Drugs; 2001; 3(6):433-7; discussion 438-9. PubMed ID: 11437188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis.
    Goldman SC; Holcenberg JS; Finklestein JZ; Hutchinson R; Kreissman S; Johnson FL; Tou C; Harvey E; Morris E; Cairo MS
    Blood; 2001 May; 97(10):2998-3003. PubMed ID: 11342423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rasburicase: a review of its use in the management of anticancer therapy-induced hyperuricaemia.
    Oldfield V; Perry CM
    Drugs; 2006; 66(4):529-45. PubMed ID: 16597166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rasburicase: a potent uricolytic agent.
    Pui CH
    Expert Opin Pharmacother; 2002 Apr; 3(4):433-42. PubMed ID: 11934348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A study of rasburicase for the management of hyperuricemia in pediatric patients with newly diagnosed hematologic malignancies at high risk for tumor lysis syndrome.
    Kikuchi A; Kigasawa H; Tsurusawa M; Kawa K; Kikuta A; Tsuchida M; Nagatoshi Y; Asami K; Horibe K; Makimoto A; Tsukimoto I
    Int J Hematol; 2009 Nov; 90(4):492-500. PubMed ID: 19701676
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention and treatment of hyperuricemia in hematological malignancies.
    Cairo MS
    Clin Lymphoma; 2002 Dec; 3 Suppl 1():S26-31. PubMed ID: 12521386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma.
    Pui CH; Mahmoud HH; Wiley JM; Woods GM; Leverger G; Camitta B; Hastings C; Blaney SM; Relling MV; Reaman GH
    J Clin Oncol; 2001 Feb; 19(3):697-704. PubMed ID: 11157020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience.
    Pui CH
    Semin Hematol; 2001 Oct; 38(4 Suppl 10):13-21. PubMed ID: 11694947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant urate oxidase (Rasburicase) for the treatment of hyperuricemia in pediatric patients with hematologic malignancies: Results of a compassionate prospective multicenter study in Korea.
    Shin HY; Kang HJ; Park ES; Choi HS; Ahn HS; Kim SY; Chung NG; Kim HK; Kim SY; Kook H; Hwang TJ; Lee KC; Lee SM; Lee KS; Yoo KH; Koo HH; Lee MJ; Seo JJ; Moon HN; Ghim T; Lyu CJ; Lee WS; Choi YM
    Pediatr Blood Cancer; 2006 Apr; 46(4):439-45. PubMed ID: 16123985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rasburicase for the treatment and prevention of hyperuricemia.
    Yim BT; Sims-McCallum RP; Chong PH
    Ann Pharmacother; 2003; 37(7-8):1047-54. PubMed ID: 12841818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urate oxidase for the prevention and treatment of tumor lysis syndrome in children with cancer.
    Cheuk DK; Chiang AK; Chan GC; Ha SY
    Cochrane Database Syst Rev; 2010 Jun; (6):CD006945. PubMed ID: 20556770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention and treatment of hyperuricemia with rasburicase in children with leukemia and non-Hodgkin's lymphoma.
    Rényi I; Bárdi E; Udvardi E; Kovács G; Bartyik K; Kajtár P; Masát P; Nagy K; Galántai I; Kiss C
    Pathol Oncol Res; 2007; 13(1):57-62. PubMed ID: 17387390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spotlight on rasburicase in anticancer therapy-induced hyperuricemia.
    Oldfield V; Perry CM
    BioDrugs; 2006; 20(3):197-9. PubMed ID: 16724869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and (pharmaco)kinetics of one single dose of rasburicase in patients with chronic kidney disease.
    Sestigiani E; Mandreoli M; Guardigli M; Roda A; Ramazzotti E; Boni P; Santoro A
    Nephron Clin Pract; 2008; 108(4):c265-71. PubMed ID: 18418005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of Therapeutic Effect of Rasburicase on Hyperuricemia Associated with Chemotherapy Based on Theoretical Model.
    Kimura K; Kanehira N; Takayanagi R; Minohara H; Homma M; Yamada Y
    Biol Pharm Bull; 2016; 39(5):705-11. PubMed ID: 27150142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rasburicase: potential role in managing tumor lysis in patients with hematological malignancies.
    Goldman SC
    Expert Rev Anticancer Ther; 2003 Aug; 3(4):429-33. PubMed ID: 12934655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitek), in the management of malignancy-associated hyperuricemia in pediatric and adult patients: final results of a multicenter compassionate use trial.
    Jeha S; Kantarjian H; Irwin D; Shen V; Shenoy S; Blaney S; Camitta B; Pui CH
    Leukemia; 2005 Jan; 19(1):34-8. PubMed ID: 15510203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of single-dose rasburicase in an obese female.
    Arnold TM; Reuter JP; Delman BS; Shanholtz CB
    Ann Pharmacother; 2004 Sep; 38(9):1428-31. PubMed ID: 15292497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant urate oxidase (rasburicase) in the prophylaxis and treatment of tumor lysis syndrome.
    Jeha S; Pui CH
    Contrib Nephrol; 2005; 147():69-79. PubMed ID: 15604607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single dose of rasburicase is sufficient for the treatment of hyperuricemia in patients receiving chemotherapy.
    Liu CY; Sims-McCallum RP; Schiffer CA
    Leuk Res; 2005 Apr; 29(4):463-5. PubMed ID: 15725482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.